Ipca Laboratories Ltd Q2 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/g48n46dowgnrmeszpgtafbju.pdf

Key Takeaways


Domestic Formulation: Steady Growth, Mix Shift Underway

A.K. Jain: "Yes, because the product mix is improving, and that's giving the better margin. So we are giving that guideline."

Export Formulations: One Product Obscures an Otherwise Healthy Quarter

A.K. Jain: "But overall, for the year, I have no doubt that, that kind of growth will not be achieved."

API Business: The Quarter’s Growth Engine


Unichem: A Multi-Year Turnaround, Not a Quick Fix

A.K. Jain: "The business also has to mature because business starts, so it will take time. So, let's say, I would say it may -- for that margins to go up, it may be around 1.5 to 2 years."

Margins: Mix-Driven Upside, Guidance Lifted


Pipeline & Strategic Bets: Early Innings on Multiple Fronts

A.K. Jain: "So we will not be there in that kind of race for -- in the current phase of the product. But next phase of product, whenever it comes, we'll be there."

Guidance & Commitments

CommitmentSpecificsTimeline
Domestic formulation growth~10–11% for the full yearFY26
Generic formulation growth~8–9% in H2 FY26H2 FY26
API full-year growth~14%FY26
Consolidated EBITDA margin~1% better than the ~20% baseline (raised from prior guidance of a ~25 bps decline)H2 FY26
R&D spend~4% of turnover, rising to ~4.5–4.75% once biosimilar clinical trials beginFY26; next financial year
Unichem margin improvementMeaningful expansion only after dossier approvals and API sourcing shifts1.5 to 2 years
Unichem API sourcing from IpcaQualification applications filed; major APIs to start supplying after regulatory clearanceNext financial year, after 6–9 month clearance process
Unichem dossier-driven market expansionProducts taken to Europe, Australia, New Zealand, Canada, ROW after 12–18 month registration process2 to 3 years
Biosimilar clinical trials3 of 7 projects expected to enter trialsNext year

Key Metrics

MetricQ2 FY26
Domestic formulation revenue growth~8% YoY
Export formulation revenue₹493 cr, declined ~9% YoY from ₹541 cr
API business revenue₹408 cr, +28% YoY from ₹319 cr
Standalone EBITDA margin~25.46%, improved ~2.57 ppt YoY from 22.89%
Consolidated EBITDA margin~21.68%, improved ~2.58 ppt YoY from 19.1%
R&D spend3.91% of turnover, up from 2.7% in Q2 FY25
Full-year consolidated margin guidance~20%, expected to be better by ~1% in H2 FY26
Full-year API business growth guidance~14%
H2 FY26 generic formulations growth guidance~8% to 9%
Ipca market share (MAT September 2025)2.8%, improved from 2.3% in MAT September 2024
Chronic business share of overall Ipca business~35%, up from 34% last quarter
Pain segment growth~10% YoY
Cardiovascular segment growth~11% YoY
CNS segment growth~18% YoY
Unichem Q2 EBITDA~₹60 cr, ~11% margin
Ipca U.S. business H1 FY26 revenue~₹55 cr
Field force~7,000 medical reps